7:11 AM ET
8-K
Business Update
Armata Pharmaceuticals Business Update
Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its AP-SA02 bacteriophage candidate. This incremental funding brings the total cumulative government support for the program to $32.4 million and is intended to fund activities for a pivotal superiority study in complicated S. aureus bacteremia.
- Counterparty
- U.S. Department of War